New NASDAQ Alert [Inside]

AwesomeStocks Hello! New Alert: Mainz Biomed B.V. (NASDAQ: MYNZ) Today, we would like to bring to your attention a previous winner and a new breakout opportunity. We first alerted MYNZ in October after which it rallied + 38% to a high of 9.61 in November. We again brought MYNZ to your attention in late February after which it rallied +7%. Since our last update, MYNZ has consolidated those gains and now could be presenting another breakout opportunity. Furthermore, MYNZ announced multiple developments recently... Including yesterday’s big breaking news. As a reminder, MYNZ is a Nasdaq company that recently had its IPO in 2021. MYNZ is aiming to become a “leading provider of easy-to-use diagnostic solutions for patients everywhere”. MYNZ develops “market-ready molecular genetic diagnostic solutions for life-threatening conditions”. Technology is making early disease detection & diagnosis easier and more available to consumers. This is becoming more important with a growing elderly population. Currently, there are “112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years”. According to the Mayo Clinic, “a majority of people with colon cancer are older than 50”. Colorectal cancer is the “second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%”. “The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the US, with 52,980 resulting in death.” The company’s “flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test” for colorectal cancer. Importantly, “ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy”. The test “utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT)”. Not only that, but also, it is “designed to detect tumor DNA and CRC cases in their earliest stages”. This is an important distinction because “many people with colon cancer experience no symptoms in the early stages of the disease”. ColoAlert is “currently marketed across Europe and in select international territories”. In addition, MYNZ is currently running a “pivotal FDA clinical study for U.S. regulatory approval”. The company’s “product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples”. MYNZ has announced multiple accomplishments over the past few months. In January, the company announced: “Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert” - “As a start, ColoAlert has been integrated into BGM (“betriebliches Gesundheitsmanagement”), a corporate health network providing services to employees at forty-eight of the fifty largest companies in Germany1.” In February, the company announced: “Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK” - “The addressable market in Spain is estimated at 26 million patients and at 9 million patients in the greater London region.” In addition, the company also announced: “Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program” Here are the company’s comments from this press release: ““This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler.” Since our last alert, MYNZ has announced several important developments. On March 8, the company announced: “Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection” Here are the highlights from this press release: - “Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals” - “Patient Education Day in the City of Mainz, Germany, where the Company is headquartered” - “Germany-based molecular diagnostic specialist to support local colorectal cancer communities” On March 15, the company announced: “Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany” - “Labor Staber to actively market and sell ColoAlert to its physician and patient network.” In addition, yesterday, the company announced potentially very big news: “Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas” Here are the highlights from this press release: - “Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effective” - “Two mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced adenoma samples” - “eAArly DETECT clinical trial evaluating these biomarkers with fresh samples reporting results mid-year 2023” - “Results of eAArly DETECT will inform possible inclusion in U.S. Pivotal Clinical Trial (ReconAAsense) assessing Company’s CRC detection test” - “ReconAAsense represents an opportunity to achieve gold standard status for self-administered colorectal cancer (CRC) screening” MYNZ has multiple catalysts in its favor to experience increased growth potential. Make sure to do your own due diligence. Sources: [Mayo]( [PR1]( [PR2]( [PR3]( [PR4]( [PR5]( [PR6]( [PR7]( [PR8]( [PR9]( [PR10]( [PR11]( [Website]( [Chart]( Happy Trading! AwesomeStocks Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. DISCLAIMER You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated twelve thousand four hundred sixty five dollars by bank wire transfer on 3/27/23 for the distribution of this advertisement about MYNZ dated 3/30/23. Previously, owners and operators of the Publisher have been compensated twelve thousand five hundred dollars by bank wire transfer on 2/24/23 for the distribution of a prior advertisement about MYNZ. Previously, owners and operators of the Publisher have been compensated eighteen thousand dollars by bank wire transfer on 10/7/22 for the distribution of a prior advertisement about MYNZ. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. Our records indicate that {EMAIL} requested and confirmed to be added to AwesomeStocks.com on March 5, 2023. [Click Here To Unsubscribe]( 6020 Bent Pine Dr Orlando Florida 32822 USA [Unsubscribe]( | [Change Subscriber Options](